BOSTON--(BUSINESS WIRE)--Daphne Zohar, Co-founder and Chief Executive Officer of PureTech Health plc, (LSE: PRTC), a cross-disciplinary biotech company tackling fundamental healthcare needs in disruptive ways, yesterday was named the EY Entrepreneur Of The Year® 2016 in the New England program. The awards program, which is celebrating its 30th year, recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their businesses and communities.
“It’s an honor to be recognized among this distinguished group of business leaders and innovators,” said Zohar. “The New England region has truly become a hub for fostering an entrepreneurial spirit and new ideas.”
Sponsors
Founded and produced
by EY, the Entrepreneur Of The Year Awards are nationally sponsored by
SAP America, Merrill Corporation and the Ewing Marion Kauffman
Foundation. In New England, sponsors also include fama PR, Goodwin
Procter, the Isenberg School of Management at the University of
Massachusetts Amherst, Nixon Peabody, True, Chatham Financial, Empire
Valuation, Morgan Lewis and T3 Advisors.
About Daphne Zohar
Ms. Daphne Zohar is Co-Founder and Chief
Executive Officer of PureTech
Health (PRTC.L) and a member of the
Company’s Board of Directors. Zohar is an entrepreneur who built a new
kind of biotech company in PureTech. Zohar assembled a leading team to
help implement her vision, and she has attracted over $450 million to
the Company and its businesses. Zohar has been recognized as a top
leader and innovator in biotechnology by a number of sources, including BioWorld,
MIT's Technology Review, the Boston Globe and Scientific
American. She sits on the boards of PureTech Health, The
Sync Project, Akili
Interactive Labs, Follica,
Karuna
Pharmaceuticals and Tal
Medical. She also sits on the Technology Development Fund Advisory
Board at Children's Hospital Boston and is an Editorial Advisor to
Xconomy, a national news company.
About PureTech Health
PureTech
Health (PureTech Health plc, PRTC.L) is a cross-disciplinary biotech
company focused on areas of growing scientific and technical insights
that it believes are at an important inflection point, including the
central nervous, gastro-intestinal and immune systems, and the
interactions and signalling between them. PureTech has approximately 20
clinical studies across its pipeline targeting multi-billion dollar
market opportunities, including five human proof-of-concept studies and
multiple pivotal or registration study readouts expected in the next two
years. While inevitably some technologies will not advance to
commercialisation, PureTech’s approach mitigates risk as most of the
cash resides on a PureTech parent company level, allowing PureTech to
build value and divert cash to its most successful programmes as
milestones are achieved. PureTech has over 220 patents and patent
applications. PureTech's leading team and board, along with an advisory
network of more than 60 expert founder-scientists and advisors across
multiple disciplines, gives PureTech access to potentially
ground-breaking science and technological innovation. With healthcare
undergoing major transformation, PureTech believes it is well positioned
to develop and launch medicines for the 21st century. For more
information, visit www.puretechhealth.com
and connect with us on Twitter.
About EY Entrepreneur Of The Year®
EY
Entrepreneur Of The Year is the world’s most prestigious business award
for entrepreneurs. The unique award makes a difference through the way
it encourages entrepreneurial activity among those with potential and
recognizes the contribution of people who inspire others with their
vision, leadership and achievement. As the first and only truly global
award of its kind, Entrepreneur Of The Year celebrates those who are
building and leading successful, growing and dynamic businesses,
recognizing them through regional, national and global awards program in
more than 145 cities in more than 60 countries.
